subscribe
 

Public to see impact of medical research funding

Europe’s largest store of open-access biomedical literature has joined forces with a leading online research outcomes system to connect research articles and grants with data on their impact.

‘Next generation’ cancer drug shows promise in early trial

A new potential cancer drug has shown promising results in an early stage clinical trial. The drug, called AUY922, could help lead to a new way to treat a wide range of cancers including breast and lung cancer.

Cobra Biologics and Novolytics unveil successful development of bacteriophages against bacterial infection

Cobra Biologics and Novolytics have announced a breakthrough in the development of two Staphylococcus aureus based phage products for Phase I clinical trials with a 100 fold increase in upstream process yields.

Plasticell Ltd and Progenitor Labs join thriving community at SBC

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants.

Roche's RoACTEMRA approved in EU to treat children with rare form of arthritis

Roche has announced that the European Medicines Agency has approved RoACTEMRA to treat children with polyarticular juvenile idiopathic arthritis (PJIA), a rare, chronic and debilitating form of childhood arthritis.

Researchers reveal malaria's deadly grip

International researchers have identified how malaria parasites growing inside red blood cells stick to the sides of blood vessels in severe...

Curie-Cancer and Biolog-id sign partnership agreement

Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations

Sub-Visible Particles: impact on therapeutic proteins

SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation...

Arthritis Research UK - Promoting effective and efficient reporting

In a world increasingly focused on accountability, over 30 leading research funding organisations including Arthritis Research UK have joined forces to use a new research outcomes reporting system called Researchfish.

Patients at risk of heart disease set to benefit from clinical trial

Patients suffering from high blood pressure - the single most important risk for death worldwide - could be helped by a UK-wide clinical trial aimed at improving treatments.

Auxogyn selected to present at European BioEquity Conference in Stockholm

BioEquity is the top European event for life science investors showcasing companies on the forefront of innovation.

Transgene announces its invesment in ElsaLys Biotech

The Start-up company will develop therapeutic antibodies against novel targets in the fields of cancer and inflammation.

Drug candidates hold promise for HIV drugs market

Patients to benefit from potential for improved efficacy in less commonly used types of antiretroviral therapies and one-pill-daily combination drugs

Development and licensing deals speed up new drug development

Technology licensing tie-ups and more targeted discovery solutions are driving new drug developments

Queen’s scientists develop ‘magic bullet’ nanomedicine for Acute Lung Injury

Researchers at Queen’s University Belfast have devised a ‘magic bullet’ nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

Novartis drug Ilaris® approved by FDA

Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.

World Lupus Day

Oxford Gene Technology marks World Lupus Day with announcement of novel biomarker panel to support earlier SLE diagnosis

European multidisciplinary conference in thoracic oncology

New data presented at EMCTO showed that first-line therapy with gefitinib (IRESSATM) in Caucasian patients with EGFR mutation-positive advanced NSCLC resulted in an ORR of 70% (95% CI 61-78)

New nanoparticles research

A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.

Study finds nearly 5 million asthmatics worldwide could benefit from antifungal therapy

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

Pages

Newsbrief

Twitter Icon © Setform Limited
subscribe